ArticleeLife2021
Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection.
Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review.Human vaccines & immunotherapeutics · 2022Pooled it
- Pooled it
- Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Pooled it
- Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021Pooled it
- Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial.Nature medicine · 2022Trial
- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.The New England journal of medicine · 2021Trial
- Improving vaccine communication to the often-overlooked young adult population: A qualitative study of 20-29 year olds in British Columbia, Canada.Human vaccines & immunotherapeutics · 2025Article
- Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2.American journal of epidemiology · 2023Observational
- COVID-19 vaccination challenges: A mini-review.Human vaccines & immunotherapeutics · 2022Review
- Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination.iScience · 2022Article
- A Macro-Level Association of Vaccination Rate with the Number of Confirmed COVID-19 Cases in the United States and Japan.International journal of environmental research and public health · 2022Article
- Article
- An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Observational
- COVID-19 vaccine intention among young adults: Comparative results from a cross-sectional study in Canada and France.Vaccine · 2022Article
- Evolution of Responses to COVID-19 and Epidemiological Characteristics in South Korea.International journal of environmental research and public health · 2022Article
- A COVID-19 vaccination model for Aotearoa New Zealand.Scientific reports · 2022Article
- Indirect Protection by Reducing Transmission: Ending the Pandemic With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination.Open forum infectious diseases · 2022Article
- Asymptomatic and pre-symptomatic infection in Coronavirus Disease 2019 pandemic.Medical review (2021) · 2022Review
- Prevention of host-to-host transmission by SARS-CoV-2 vaccines.The Lancet. Infectious diseases · 2022Review
- Actions and attitudes on the immunized patients against SARS-CoV-2.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of asymptomatic SARS-CoV-2 infection remains unknown. We previously demonstrated frequent pauci- and asymptomatic SARS-CoV-2 infection amongst healthcare workers (HCWs) during the UK's first wave of the COVID-19 pandemic, using a comprehensive PCR-based HCW screening programme (Rivett et al., 2020; Jones et al., 2020). Here, we evaluate the effect of first-dose BNT162b2 vaccination on test positivity rates and find a fourfold reduction in asymptomatic infection amongst HCWs ≥12 days post-vaccination. These data provide real-world evidence of short-term protection against asymptomatic SARS-CoV-2 infection following a single dose of BNT162b2 vaccine, suggesting that mass first-dose vaccination will reduce SARS-CoV-2
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.